398487-31-5

Basic information

• Product Name: 6-Quinolinecarbonitrile, 4-chloro-7-methoxy-
• CAS NO: 398487-31-5
• Molecular Formula: C11H7ClN2O
• Molecular Weight: 218.642
• Mol File: 398487-31-5.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: 6-Quinolinecarbonitrile, 4-chloro-7-methoxy-(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Quinolinecarbonitrile, 4-chloro-7-methoxy-(398487-31-5)
• EPA Substance Registry System: 6-Quinolinecarbonitrile, 4-chloro-7-methoxy-(398487-31-5)

Safety Data

• Hazardous Substances Data: 398487-31-5(Hazardous Substances Data)

Upstream product

• 609785-70-8 N-tert-butoxycarbonyl-4-cyano-3-methoxyaniline 
• 101084-96-2 2-methoxy-4-nitrobenzonitrile 
• 28163-00-0 4-nitro-2-chlorobenzonitrile 
• 7251-09-4 4-amino-2-methoxybenzonitrile 
• 67608-58-6 4-cyano-3-hydroxy-aniline 
• 67-56-1 methanol 
• 1101109-32-3 2-amino-5-cyano-4-methoxybenzoic acid 

Downstream Products

• 417716-92-8 lenvatinib 
• 1882873-21-3 1-{2-chloro-4-[(6-cyano-7-methoxy-quinolin-4-yl)oxy]phenyl}-3-cyclopropylurea 

Relevant articles and documents

IMINO SULFANONE INHIBITORS OF ENPP1

The present disclosure relates generally to inhibitors of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1), compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to sulfoximine- based inhibitors of ENPP1 of Formula (I) and methods of their use for treating disease mediated by ENPP1.

Preparation method of lenvatinib

The invention discloses a preparation method of lenvatinib, which comprises the following steps: by using 4-nitro-2-chlorobenzonitrile as an initial raw material, introducing nitro into molecules forelectron withdrawing, thereby greatly lowering the elect

QUINOLINE DERIVATIVES

The invention concerns quinoline derivatives of Formula (I): or a pharmaceutically-acceptable salt thereof, wherein each of X1, p, R1, q, R2, R3, R4, R5, Ring A, r and R6 has any of the meanings defined hereinbefore in the description; processes for their preparation, pharmaceutical compositions containing them and their use in the manufacture of a medicament for use in the treatment of cell proliferative disorders.